Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Drug

Sino Biopharmaceutical’s Rovadicitinib Granted Breakthrough Therapy Designation for Chronic Graft-versus-Host Disease

Fineline Cube Aug 7, 2025

China-based Sino Biopharmaceutical Limited (HKG: 1177) announced that its self-developed JAK/ROCK dual small molecule inhibitor,...

Company Deals

Guangzhou Innogen Pharmaceuticals Launches H-Share Global Offering in Hong Kong

Fineline Cube Aug 7, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) officially launched its H-share global offering...

Company

BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales

Fineline Cube Aug 7, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...

Company Medical Device

Sino Medical Sciences’ COMETIU Stent System and COMEX Catheter Receive FDA Breakthrough Designation

Fineline Cube Aug 7, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received breakthrough devices...

Company Deals

Novartis Evaluates Acquisition of Avidity Biosciences to Strengthen Rare Disease Pipeline

Fineline Cube Aug 7, 2025

According to reports from several news organizations citing insider sources, that Novartis AG (NYSE: NVS)...

Policy / Regulatory

Shanghai Issues New Measures to Boost Commercial Health Insurance for Biopharmaceutical Innovation

Fineline Cube Aug 7, 2025

On August 6, 2025, seven Shanghai-based authorities jointly issued a notice titled “Several Measures on...

Company Drug

Hengrui’s Trastuzumab Rezetecan Granted FDA Orphan Drug Designation for Gastric Cancer Treatment

Fineline Cube Aug 7, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that it has received...

Company

Pfizer’s Q2 2025 Revenue Rises 10% Driven by Strong Biopharma Sales

Fineline Cube Aug 6, 2025

US-based Pfizer Inc. (NYSE: PFE) reported Q2 2025 financial results, revealing a 10% year-on-year (YOY)...

Company

Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales

Fineline Cube Aug 6, 2025

Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...

Company Drug

Qyuns Therapeutics’ QX004N Enters Phase 3 Trials for Psoriasis and Crohn’s Disease

Fineline Cube Aug 6, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that QX004N, an interleukin-23 subunit p19...

Company Drug

Sino Biopharmaceutical’s TQC3302 Approved for COPD Maintenance Treatment Clinical Trials

Fineline Cube Aug 6, 2025

Sino Biopharmaceutical Limited (HKG: 1177) announced that its independently developed Category 2.3 modified new drug,...

Company Drug

Humanwell Healthcare Receives NMPA Approval for HW241045 IPF Clinical Trials

Fineline Cube Aug 6, 2025

China-based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its wholly-owned subsidiary, Humanwell Innovation...

Company Drug

Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy

Fineline Cube Aug 6, 2025

China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...

Company Drug

CSPC Pharmaceutical’s Semaglutide Injection NMPA Marketing Application Accepted

Fineline Cube Aug 6, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its semaglutide...

Company Drug

Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China

Fineline Cube Aug 6, 2025

Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...

Company Deals

ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D

Fineline Cube Aug 5, 2025

Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...

Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Medical Device

Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu

Fineline Cube Aug 5, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...

Company Drug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Fineline Cube Aug 5, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...

Company Drug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Fineline Cube Aug 5, 2025

China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...

Posts pagination

1 … 112 113 114 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.